Biomarker Commons

8 Questions about Biomarker Commons

Biomarker Commons launched just over three years ago with the goal of aggregating the latest biomarker and personalized medicine news.

Now, we really need your feedback. We've got 8 simple questions that should take you less than 5 minutes to complete. Please let us know how we've been doing and what we can do to improve our service.


OGT Launches PGS Array to Improve the Chances of Successful IVF

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has announced the launch of a new pre-implantation genetic screening (PGS) array aimed at improving the chances of successful in-vitro fertilisation (IVF).

The array detects chromosome number abnormalities (aneuploidy) across all 24 human chromosomes using DNA amplified from a single cell from an early-stage embryo. This allows selection of an embryo with a normal chromosomal content.


Arno Therapeutics to Collaborate with Veridex on Development of Diagnostic Test

Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, recently announced that it has signed an agreement with Veridex, LLC, a Johnson & Johnson company, to develop a diagnostic test to detect the presence of activated progesterone receptors (APRs) as a potential biomarker of anti-progestin activity in circulating tumor cells (CTCs).


Cancer Genetics Signs Agreement with MultiPlan

Cancer Genetics, Inc. (OTCQB: CGIX) ("CGI" or the "Company"), a leader in oncology-focused personalized medicine, has entered into an agreement with MultiPlan, Inc. (“MultiPlan”), the industry’s most comprehensive provider of healthcare cost management solutions.


MET Protein Levels Show Promise as Biomarker for Aggressive Colon Cancer

MET protein levels correlate strongly with epithelial-mesenchymal transition (EMT) phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center.

The study results, which compared MET protein expression with protein/gene expression of EMT markers and evaluated impact on survival, were released recently at the annual meeting of the American Society of Clinical Oncology.